News

HCVC leads kyron.bio €5.5M round to use glycan engineering for advanced drug design

The company has developed the first-ever platform to unlock precision control over glycans, essential sugar molecules found on the surface…

7 months ago

Alpha Tau to Present at Jefferies Global Healthcare Conference

JERUSALEM, May 28, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the…

7 months ago

iTeos Therapeutics Announces Its Intention to Wind Down Operations

- Board of Directors intends to cease operations - Company to focus efforts on selecting best path to deliver near-term…

7 months ago

Vittoria Biotherapeutics to Share Trials-in-Progress Presentation from Phase 1 Study of VIPER-101 at ASCO 2025 Annual Meeting

Trial is evaluating VIPER-101, a novel, gene edited, autologous dual-population CAR-T therapy in patients with T-cell lymphomaPHILADELPHIA, May 28, 2025…

7 months ago

SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study

First new patient dosed in Phase 3 MARIO study following the lifting of the FDA clinical holdResumption of dosing in…

7 months ago

Glucotrack Strengthens Board of Directors with Election of Victoria E. Carr-Brendel, PhD

Experienced medical device executive with deep expertise in implantable technologies joins Glucotrack as Company advances development of long-term implantable blood…

7 months ago

Achieve Life Sciences to Present at the Jefferies Global Healthcare Conference

SEATTLE and VANCOUVER, British Columbia, May 28, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage specialty…

7 months ago

Ernexa Therapeutics Announces New Data to be Presented at ASCO Annual Meeting 2025

New data finds novel cell therapy successfully converts “cold” ovarian tumors into “hot,” demonstrating potential to unlock immune response and…

7 months ago

Monarch Therapeutics and SNAP Biosciences, Inc., a Subsidiary of Coeptis Therapeutics Holdings Inc., Enter Licensing Agreement to Bolster SNAP-CAR NK Cell Therapy in Oncology

WEXFORD, Pa. and PRINCETON, N.J., May 28, 2025 (GLOBE NEWSWIRE) -- SNAP Biosciences, Inc a majority-owned subsidiary of Coeptis Therapeutics…

7 months ago

SeaStar Medical Announces CMS Coverage for Medicare and Medicaid Eligible Patients with Cardiorenal Syndrome Awaiting LVAD in Investigational Trial of SCD Therapy

Coverage marks SeaStar Medical’s second award by CMS for reimbursement of medical expenses for Medicare and Medicaid patients in a…

7 months ago